Loading
Cancer, Hypoxia, and Metabolism / Angiogenesis and VEGF in Cancer · Journal article
Medcomm – Oncology · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes the molecular mechanisms and immunomodulatory roles of nitric oxide in cancer and proposes therapeutic strategies based on NO donors and delivery platforms. It identifies a concentration-dependent dual role of NO—acting as both tumor promoter and suppressor—but does not present primary efficacy or safety data from clinical trials or controlled experiments. The work frames unresolved translational bottlenecks (targeted delivery, controlled release, therapeutic windows) as priorities but does not test or validate them.
Journal article.
NO exhibits concentration-dependent biphasic effects on cancer progression, acting as either tumor promoter or suppressor. Molecular mechanisms span soluble guanylate cyclase–cGMP signaling, protein S-nitrosylation, and peroxynitrite-driven nitrosative stress. NO influences tumor cell proliferation, metabolism, angiogenesis, therapy resistance, and antitumor immunity across innate and adaptive compartments.
Abstract presents no quantitative efficacy or safety data, phase of development, or clinical trial results.
The source did not state who this applies to in practice.
A narrative review synthesizing mechanistic concepts and therapeutic strategies without presenting primary empirical data, clinical trials, or meta-analyses; raises questions about NO-based cancer interventions rather than testing them.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Nitric oxide (NO) is an endogenous gasotransmitter that influences cancer progression in a concentration‐dependent manner, acting as either a tumor promoter or suppressor. Although this dual role is recognized, an integrated framework systematically linking its molecular mechanisms, immunomodulatory functions, and therapeutic translation is lacking, limiting rational design of NO‐based anticancer interventions. This review analyzes the molecular basis of the concentration‐dependent biphasic effects of NO, spanning canonical soluble guanylate cyclase‐cyclic guanosine monophosphate (cGMP) signaling, protein S‐nitrosylation (SNO), and peroxynitrite‐driven nitrosative stress. It then examines how these signaling pathways drive the direct effects of NO on tumor cell proliferation, metabolism, angiogenesis, and therapy resistance. It further delineates how these effects, together with NO‐mediated immunomodulation, define a dual role that encompasses both tumor cell‐intrinsic processes and antitumor immunity across innate and adaptive compartments. The therapeutic translation of these mechanistic insights is examined through NO donor chemistry and the integration of such donors into stimulus‐responsive delivery platforms, molecular conjugates, and combination regimens pairing NO with chemotherapy, radiotherapy, and immunotherapy. By connecting fundamental NO biology with emerging therapeutic strategies, this review offers an integrated framework to guide development of spatiotemporally controlled NO‐based interventions and identifies translational bottlenecks requiring resolution for clinical application, including targeted delivery, controlled release kinetics, and context‐dependent therapeutic windows.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.